Celltrion presents new data on CT-39 (biosimilar omalizumab)

Mar 15, 2022

The Centre for Biosimilars reported on a study on Celltrion’s CT-39 (biosimilar omalizumab) presented at the American Academy of Allergy Asthma and Immunology annual meeting.  Celltrion reported that the study demonstrated equivalence with Xolair® (omalizumab).

Print Page Mail Article